Black Diamond Therapeutics (BDTX) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategy

• Developing precision small molecule therapies for oncology, with silevertinib as the lead program targeting non-classical EGFR mutations in lung cancer and glioblastoma (GBM).

• Lean operating model provides over two years of cash runway, funding through key phase 2 readouts.

• Actively exploring partnership opportunities, especially for lung cancer, to support pivotal studies and global reach.

• Pipeline includes silevertinib, a partnered Ras/Raf inhibitor (BDTX-4933), and a preclinical FGFR inhibitor (BDTX-4876).

Clinical development highlights

• Silevertinib is a fourth-generation EGFR inhibitor designed for broad non-classical mutation coverage and high brain penetrance.

• Phase 2 trial in non-small cell lung cancer (NSCLC) shows a 60% objective response rate and 93% disease control rate in frontline patients, with robust CNS responses (86%).

• Over a third of enrolled patients had untreated brain metastases, reflecting real-world populations.

• Early durability data are promising, with 29 patients remaining on therapy, some for over 19 months.

• Adverse events are typical for EGFR TKIs and manageable, with less than 10% discontinuation due to AEs.

Competitive landscape and differentiation

• Silevertinib covers a broader range of non-classical EGFR mutations than competitors like furmonertinib, with notably higher CNS response rates (86% vs. 47%).

• CNS metastases are more prevalent and problematic in non-classical EGFR NSCLC, making brain penetrance a key differentiator.

• Dose reductions are common but do not compromise efficacy; frontline patients are more sensitive to EGFR-mediated AEs.